Información del artículo
El Texto completo está disponible en PDF
Bibliografía básica
[Abajo, 1999]
Abajo F.J., García Rodríguez L.A., Montero D..
Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.
BMJ, 319 (1999), pp. 1106-1109
[Anónimo, 1998]
Anónimo.
Antiinflamatorios no esteroideos (AINEs) y selectividad sobre Cox-2.
Bol Ter Andal, 14 (1998), pp. 14-16
[Anónimo, 2002]
Anónimo.
Las supuestas ventajas de celecoxib y rofecoxib: fraude científico.
Butll Groc, 15 (2002), pp. 13-15
[Anónimo, 2003]
Anónimo.
¿Fraude en las publicaciones científicas?. Ventajas en materia de seguridad de celecoxib y rofecoxib.
Bol Ter Andal, 19 (2003), pp. 5-6
[Bekelman, 2003]
Bekelman J.E., Li Y., Gross C.P..
Scope and impact of financial conflicts of interest in biomedical research. A systematic review.
JAMA, 289 (2003), pp. 454-465
[Bombardier, 2000]
Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al.
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
N Engl J Med, 343 (2000), pp. 1520-1528
[Cooper, 2003]
Cooper R.J., Schriger D.L., Wallace R.C., Mikulich V.J., Wilkes M.S..
The quantity and quality of scientific graphs in pharmaceutical advertisements.
J Gen Intern Med, 18 (2003), pp. 294-297
[Deyo, 1997]
Deyo R.A., Psaty B.M., Simon G., Wagner E.H., Omenn G.S..
The messanger under attack. Intimidation of researchers by special interested group.
N Engl J Med, 336 (1997), pp. 1176-1179
[Fletcher, 2003]
Fletcher R.H..
Adverts in medical journals: caveat lector.
Lancet, 361 (2003), pp. 10-11
[Gérvas, 2003]
Gérvas J, Los médicos y la industria farmacéutica. Bol Asoc Madrileña Salud Mental 2003; verano:5-7.
[Gérva, 2004]
Gérvas J..
La prescripción científica en la práctica clínica. De la teoría a la práctica.
Elementos para la gestión de la prescripción y la prestación farmacéutica,
[Gibson, 2002]
Gibson E., Baylis F., Lewis S..
Dances with the pharmaceutical industry.
JAMC, 116 (2002), pp. 448-450
[Horton, 1999]
Horton R., Smith R..
Time to register randomised trials.
Lancet, 354 (1999), pp. 1138-1139
[Jones, 2002]
Jones R..
Efficacy and safety of COX-2 inhibitors. New data are encouraging but the risk-benefit ratio remains unclear.
BMJ, 325 (2002), pp. 607-698
[Jüni, 2002]
Jüni P., Rutjes A.W.S., Dieppe P.A..
Are selective COX-2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?. Adequate analysis of the CLASS trial indicates that this may not be the case.
BMJ, 324 (2002), pp. 1287-1288
[Laporte, 1991]
Laporte J.R., Carné X., Moreno V., Juan J..
Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal ant-inflammatory drugs.
Lancet, 337 (1991), pp. 85-89
[Lexchin, 2003]
Lexchin J., Bero L.A., Djulbejovic B., Clark O..
Pharmaceutical industry sponsorship and research outcome and quality: systematic review.
BMJ, 326 (2003), pp. 1167-1170
[Mata Ruíz, 2001]
Mata Ruíz I., Ortiz Lobo A..
Industria farmacéutica y psiquiatría.
Rev Asoc Esp Neuropsiq, 21 (2001), pp. 57-74
[Peiró, 2003]
Peiró S., Meneu R., Ortún V., Puig J..
Posibles problemas de objetividad, transparencia, doble publicación y autoría en el análisis coste-efectividad del celecoxib.
Gac Sanit, 17 (2003), pp. 342-344
[Shapiro, 1997]
Shapiro M.F..
Regulating pharmaceutical advertising: what will work?.
CMAJ, 156 (1997), pp. 359-361
[Silverstein, 2000]
Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al.
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatic arthritis. The CLASS study: a randomized controlled trial.
JAMA, 284 (2000), pp. 1247-1255
[Smith, 2003]
Smith R..
Medical journal and pharmaceutical companies: uneasy bedfellows.
BMJ, 326 (2003), pp. 1202-1205
[Schuchman, 1999]
Schuchman M..
Drug company threatens legal action over Canadian guidelines.
BMJ, 319 (1999), pp. 1388
[Villanueva, 2003]
Villanueva P., Peiró S.W., Librero J., Pereiró I..
Accuracy of pharmaceutical advertisements in medical journals.
Lancet, 361 (2003), pp. 27-32
[Wazana, 2000]
Wazana A..
Physicians and the pharmaceutical industry. Is a gift ever just a gift?.
JAMA, 283 (2000), pp. 373-380
[Wolfe, 1999]
Wolfe A.M., Lichtesntein D.R., Singh G..
Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.
N Engl J Med, 340 (1999), pp. 1888-1899
Copyright © 2004. Academia de Ciencias Médicas de Bilbao